For decades, A1C has served as the gold standard for assessing long-term glucose control in people with diabetes. However, it tells only part of the story. Researchers are now exploring whether metabolic flexibility could become an important biomarker in diabetes, offering a deeper understanding of metabolic health than A1C alone. …
Read More »Protecting Muscle While Treating Obesity: New Protein Targets for Older Adults on GLP-1s
The rise of highly effective GLP-1 receptor agonists and dual incretin therapies has transformed obesity treatment. Medications such as semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) are helping patients achieve levels of weight loss that were previously difficult to attain without bariatric surgery. However, as clinicians celebrate these advances, a …
Read More »Can Muscle Quality Predict Diabetes Outcomes Better Than BMI?
For decades, body mass index (BMI) has been the standard tool for assessing metabolic health and diabetes risk. However, many clinicians now question whether weight alone tells the full story. Some people with a “normal” BMI still develop insulin resistance and type 2 diabetes, while others with higher body weight …
Read More »GLP-1 Therapy and Muscle Loss: Are We Overlooking Sarcopenia Risk?
Losing 30 pounds may sound like an undeniable success story. However, what if part of that weight loss comes from muscle instead of fat? As more patients use GLP-1 medications such as semaglutide and tirzepatide, clinicians are starting to ask an important question: are these drugs quietly contributing to the …
Read More »GLP-1s and Muscle Quality: Beyond Lean Mass Preservation
Weight loss conversations often focus on a simple question: how much lean mass is preserved? However, emerging research suggests that the story is more complex. GLP-1 receptor agonists are well known for promoting weight loss and improving glycemic control, but scientists are increasingly examining how these medications influence muscle health …
Read More »GLP-1s and Exercise Performance: Do Incretins Alter Energy Utilization?
As GLP-1 receptor agonists become a mainstay in type 2 diabetes and obesity care, more patients are pairing medication with structured training programs. However, how do GLP-1 medications actually influence metabolism during exercise? Questions about fueling, endurance, fatigue, and muscle adaptation are becoming more common in clinical practice. The relationship …
Read More »GLP-1s and Lean Mass: Preserving Muscle and Strength During Rapid Weight Loss
The scale is moving fast, clothes are fitting better, and blood sugar numbers are improving. For many people using GLP-1 medications, weight loss can feel almost effortless at first. Yet beneath those encouraging changes, another question often emerges: is muscle being lost along with fat? For individuals focused on long-term …
Read More »Prescribing Exercise in Type 2 Diabetes: What the Evidence Says About Type, Dose, and Impact
Exercise is a cornerstone of type 2 diabetes care, yet clinicians often struggle with translating broad guidelines into practical, individualized “exercise prescriptions.” The focus keyword in this article, exercise prescription for type 2 diabetes, reflects a high‑intent search term that clinicians, diabetes educators, and patients frequently use when seeking actionable …
Read More »Should We Be Prescribing Exercise as a Formal Diabetes Intervention?
When treating patients with diabetes, lifestyle advice such as “eat healthy” and “stay active” is often routine. But what if we took that a step further and issued a formal exercise prescription — in other words, ordering physical activity like we would a drug? Recent research suggests that a structured …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.